MetaVia (NASDAQ:MTVA) Rating Lowered to “Sell” at Wall Street Zen

MetaVia (NASDAQ:MTVA) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

A number of other equities research analysts also recently weighed in on MTVA. Weiss Ratings reissued a “sell (d-)” rating on shares of MetaVia in a research note on Monday, December 22nd. HC Wainwright upped their target price on shares of MetaVia from $12.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $36.50.

MetaVia Stock Up 3.0%

Shares of MTVA opened at $2.43 on Friday. The stock’s fifty day simple moving average is $7.12 and its 200-day simple moving average is $8.36. The firm has a market capitalization of $5.35 million, a PE ratio of -0.29 and a beta of 0.28. MetaVia has a 12-month low of $2.32 and a 12-month high of $23.10.

MetaVia (NASDAQ:MTVA) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($1.54) EPS for the quarter, topping analysts’ consensus estimates of ($2.86) by $1.32. Analysts anticipate that MetaVia will post -3.9 EPS for the current year.

Institutional Trading of MetaVia

A hedge fund recently bought a new stake in MetaVia stock. Virtu Financial LLC purchased a new stake in MetaVia Inc. (NASDAQ:MTVA) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned approximately 0.14% of MetaVia as of its most recent filing with the Securities and Exchange Commission (SEC). 1.37% of the stock is owned by institutional investors.

MetaVia Company Profile

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.